

ment.

The limits of this study are the following: 1) the relatively small sample size; and 2) our findings may not be generalizable to other preparations of LMWH because all patients in Group B had made the bridging therapy with enoxaparin.

In any case, the results obtained are encouraging and this encourages us to go into that with further study on the matter.

References

- Bauer KA. Pros and cons of new oral anticoagulants. *Hematology Am Soc Hematol Educ Program*. 2013; 464-70.
- Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. *Arch Intern Med*. 2005;165:1095-106.
- Rojas-Hernandez CM, Garcia DA. The Novel Oral Anticoagulants. *Semin Thromb Hemost*. 2013;39(2): 117-26.
- Ruff CT, Braunwald E. Will warfarin ever be replaced? *J Cardiovasc Pharmacol Ther*. 2010;15(3):210-9.
- Weitz JI. Meeting the unmet needs in anticoagulant therapy. *Eur J Haematol*. 2010;85 Suppl 72:1-28.
- Wells G, Coyle D, Cameron C, Steiner S, Coyle K, Kelly S, et al. Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with arterial fibrillation. Therapeutic review, Canadian Agency for Drugs and Technologies in Health (CADTH), 2012.

Correspondence to:

Dr. Rocco Franco
University of Rome "Tor Vergata"
Rome, Italy
Tel: +39 06 20900691
E-mail: roccofr91@gmail.com